Sunshine Biopharma Inc. financial data

Symbol
SBFM, SBFMW on Nasdaq
Location
Fort Lauderdale, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 437% % -9.1%
Quick Ratio 207% % 43%
Debt-to-equity 28% % 11%
Return On Equity -25% % -40%
Return On Assets -19% % -36%
Operating Margin -17% % -18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,905,945 shares 145%
Common Stock, Shares, Outstanding 4,555,945 shares 128%
Entity Public Float $22,618,055 USD 111%
Common Stock, Value, Issued $4,555 USD 128%
Weighted Average Number of Shares Outstanding, Basic 4,555,945 shares 259%
Weighted Average Number of Shares Outstanding, Diluted 3,604,653 shares 8714%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $37,323,742 USD 13%
Cost of Revenue $6,343,639 USD 14%
Research and Development Expense $680,079 USD -58%
General and Administrative Expense $18,843,802 USD 25%
Operating Income (Loss) $6,523,921 USD -33%
Nonoperating Income (Expense) $15,782 USD -98%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $6,508,139 USD -58%
Income Tax Expense (Benefit) $515,502 USD -552%
Net Income (Loss) Attributable to Parent $5,992,637 USD -42%
Earnings Per Share, Basic 4 USD/shares 80%
Earnings Per Share, Diluted -0.82 USD/shares 98%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current $3,587,560 USD
Inventory, Net $14,063,706 USD 43%
Assets, Current $27,967,232 USD 7.6%
Property, Plant and Equipment, Net $598,087 USD 1.2%
Operating Lease, Right-of-Use Asset $820,489 USD 52%
Intangible Assets, Net (Excluding Goodwill) $2,009,337 USD -32%
Goodwill $0 USD
Assets $31,487,379 USD 4.8%
Accounts Payable, Current $6,137,465 USD 48%
Liabilities, Current $6,651,315 USD 47%
Operating Lease, Liability, Noncurrent $636,708 USD 45%
Liabilities $7,288,023 USD 45%
Accumulated Other Comprehensive Income (Loss), Net of Tax $320,841 USD -290%
Retained Earnings (Accumulated Deficit) $72,874,199 USD -9%
Stockholders' Equity Attributable to Parent $24,199,356 USD -3.4%
Liabilities and Equity $31,487,379 USD 4.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,713,835 USD 46%
Net Cash Provided by (Used in) Financing Activities $338,137 USD -94%
Net Cash Provided by (Used in) Investing Activities $176,024 USD 74%
Common Stock, Shares Authorized 3,000,000,000 shares 0%
Common Stock, Shares, Issued 4,555,945 shares 128%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9,306,438 USD -24%
Deferred Tax Assets, Valuation Allowance $6,967,294 USD 8.9%
Depreciation $221,550 USD 48%
Payments to Acquire Property, Plant, and Equipment $7,490 USD -88%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $6,482,068 USD -52%
Property, Plant and Equipment, Gross $1,060,556 USD
Operating Lease, Liability, Current $218,053 USD 88%
Lessee, Operating Lease, Liability, to be Paid, Year Two $201,271 USD 82%
Lessee, Operating Lease, Liability, to be Paid, Year One $212,306 USD 82%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three $190,801 USD 84%
Deferred Tax Assets, Operating Loss Carryforwards $6,460,638 USD 22%
Lessee, Operating Lease, Liability, to be Paid, Year Four $180,868 USD 85%
Additional Paid in Capital $97,376,841 USD 6.1%
Depreciation, Depletion and Amortization $64,793 USD 52%
Deferred Tax Assets, Net of Valuation Allowance $481,747 USD 173%
Interest Expense $145,414 USD 115%